Structural Revelations of TRAF2 Function in TNF Receptor Signaling Pathway

  • Jee Y. Chung
  • Miao Lu
  • Qian Yin
  • Hao Wu
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 597)

Abstract

The tumor necrosis factor (TNF) receptor (TNFR) superfamily consists of over 20 type-I transmembrane proteins with conserved N-terminal cysteine-rich domains (CRDs) in the extracellular ligand binding region, which are specifically activated by the corresponding superfamily of TNF-like ligands. Members of this receptor superfamily have wide tissue distribution and play important roles in biological processes such as lymphoid and neuronal development, innate and adaptive immune response, and cellular homeostasis. A remarkable feature of the TNFR superfamily is the ability of these receptors to induce effects either for cell survival or apoptotic cell death. The downstream intracellular mediators of cell survival signal are a group of proteins known as TNFR associated factors (TRAFs). There are currently six canonical mammalian TRAFs. This review will focus on the unique structural features of TRAF2 protein and its role in cell survival signaling.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001; 104(4):487–501.PubMedCrossRefGoogle Scholar
  2. 2.
    Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 281(5381):1305–1308.PubMedCrossRefGoogle Scholar
  3. 3.
    Loenen WA. Cd27 And (TNFR) relatives in the immune system: Their role in health and disease. Semin Immunol 1998; 10(6):417–422.PubMedCrossRefGoogle Scholar
  4. 4.
    Newton RC, Decicco CP. Therapeutic potential and strategies for inhibiting tumor necrosis factor-Alpha. J Med Chem 1999; 42(13):2295–2314.PubMedCrossRefGoogle Scholar
  5. 5.
    Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 1994; 76(6):959–962.PubMedCrossRefGoogle Scholar
  6. 6.
    Gravestein LA, Borst J. Tumor necrosis factor receptor family members in the immune system. Semin Immunol 1998; 10(6):423–434.PubMedCrossRefGoogle Scholar
  7. 7.
    Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original original cases. Am J Med Sci 1893; 105:487–511.CrossRefGoogle Scholar
  8. 8.
    Carswell EA, Old LJ, Kassel RL et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72(9):3666–3670.PubMedCrossRefGoogle Scholar
  9. 9.
    Pennica D, Nedwin GE, Hayflick JS et al. Human tumour necrosis factor: Precursor structure, expression and homology to lymphotoxin. Nature 1985; 312(5996):724–729.CrossRefGoogle Scholar
  10. 10.
    Wang AM, Creasey AA, Ladner MB et al. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 1985; 228(4696):149–154.PubMedCrossRefGoogle Scholar
  11. 11.
    Shirai T, Yamaguchi H, Ito H et al. Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Nature 1985; 313(6005):803–806.PubMedCrossRefGoogle Scholar
  12. 12.
    Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986; 320(6063):584–588.PubMedCrossRefGoogle Scholar
  13. 13.
    Goeddel DV, Aggarwal BB, Gray PW et al. Tumor necrosis factors: Gene structure and biological activities. Cold Spring Harb Symp Quant Biol 1986: 51(Pt 1):597–609.PubMedGoogle Scholar
  14. 14.
    Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. Febs Lett 1991; 285(2):199–212.PubMedCrossRefGoogle Scholar
  15. 15.
    Lewis M, Tartaglia LA, Lee A et al. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA 1991; 88(7):2830–2834.PubMedCrossRefGoogle Scholar
  16. 16.
    Rothe M, Wong SC, Henzel WJ et al. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994; 78(4):681–692.PubMedCrossRefGoogle Scholar
  17. 17.
    Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs)—A family of adapter proteins that regulates life and death. Genes Dev 1998; 12(18):2821–2830PubMedGoogle Scholar
  18. 18.
    Chung JY, Park YC, Ye H et al. All Trafs are not created equal: Common and distinct molecular mechanisms of TRAF-mediated signal transduction. Cell Sci 2002; 115(Pt 4):679–688.Google Scholar
  19. 19.
    Cheng G, Cleary AM, Ye ZS et al. Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science 1995; 267(5203):1494–1498.PubMedCrossRefGoogle Scholar
  20. 20.
    Mosialos G, Birkenbach M, Yalamanchili R et al. The epstein-barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995; 80(3):389–399.PubMedCrossRefGoogle Scholar
  21. 21.
    Sato T, Irie S, Reed JC. A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40. FEBS Lett 1995; 358(2):113–118.PubMedCrossRefGoogle Scholar
  22. 22.
    Regnier CH, Tomasetto C, Moog-Lutz C et al. Presence of a new conserved domain in Cartl, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. J Biol Chem 1995; 270(43):25715–25721.PubMedCrossRefGoogle Scholar
  23. 23.
    Ishida TK, Tojo T, Aoki T et al. TRAF5 a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling. Proc Natl Acad Sci USA 1996; 93(18):9437–9442.PubMedCrossRefGoogle Scholar
  24. 24.
    Nakano H, Oshima H, Chung W. et al. TRAF5, an activator of NF-Kappab and putative signal transducer for the lymphotoxin-beta receptor. J Biol Chem 1996; 271(25):14661–14664.PubMedCrossRefGoogle Scholar
  25. 25.
    Mizushima S, Fujita M, Ishida T et al. Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5). Gene 1998; 207(2):135–140.PubMedCrossRefGoogle Scholar
  26. 26.
    Cao Z, Xiong J, Takeuchi M et al. TRAF6 is a signal transducer for Interleukin-1. Nature 1996; 383(6599):443–446.PubMedCrossRefGoogle Scholar
  27. 27.
    Ishida T, Mizushima S, Azuma S et al. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem 1996; 271(46):28745–28748.PubMedCrossRefGoogle Scholar
  28. 28.
    Bouwmeester T, Bauch A, Ruffner H et al. A physical and functional map of the human TNF-Alpha/NF-Kappa B signal transduction pathway. Nat Cell Biol 2004; 6(2):97–105.PubMedCrossRefGoogle Scholar
  29. 29.
    Xu LG, Li LY, Shu HB. TRAF7 potentiates MEKK3-induced AP1 and CHOP activation and induces apoptosis. J Biol Chem 2004; 279(17):17278–17282.PubMedCrossRefGoogle Scholar
  30. 30.
    Ghosh S, Karin M. Missing pieces in the NF-KappaB puzzle. Cell 2002; 109(Suppl):S81–96:S81–S96.CrossRefGoogle Scholar
  31. 31.
    Shaulian E, Karin M. Ap-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4(5):E131–E136.PubMedCrossRefGoogle Scholar
  32. 32.
    Trompouki E, Hatzivassiliou E, Tsichritzis T et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-Kappab activation by TNFR family members. Nature 2003; 424(6950):793–796.PubMedCrossRefGoogle Scholar
  33. 33.
    Brummelkamp TR, Nijman SM, Dirac AM et al. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-KappaB. Nature 2003; 424(6950):797–801.PubMedCrossRefGoogle Scholar
  34. 34.
    Kovalenko A, Chable-Bessia C, Cantarella G et al. The tumour suppressor cyld negatively regulates NF-KappaB signalling by deubiquitination. Nature 2003; 424(6950):801–805.PubMedCrossRefGoogle Scholar
  35. 35.
    Hsu H, Shu HB, Pan MG et al. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996; 84(2):299–308.PubMedCrossRefGoogle Scholar
  36. 36.
    Stanger BZ, Leder P, Lee TH et al. RIP: A novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 1995;81(4):513–523.PubMedCrossRefGoogle Scholar
  37. 37.
    Hsu H, Huang J, Shu HB et al. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996; 4(4):387–396.PubMedCrossRefGoogle Scholar
  38. 38.
    Yeh WC, Shahinian A, Speiser D et al. Early lethality, functional NF-KappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity 1997; 7(5):715–725.PubMedCrossRefGoogle Scholar
  39. 39.
    Kelliher MA, Grimm S, Ishida Y et al. The death domain kinase RIP mediates the TNF-induced NF-KappaB signal. Immunity 1998; 8(3):297–303.PubMedCrossRefGoogle Scholar
  40. 40.
    Wang CY, Mayo MW, Korneluk RG et al. NF-KappaB antiapoptosis: Induction of TRAF1 and TRAF2 and C-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281(5383):1680–1683.PubMedCrossRefGoogle Scholar
  41. 41.
    Irmler M, Thome M, Hahne M et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388(6638):190–195.PubMedCrossRefGoogle Scholar
  42. 42.
    Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114(2):181–190.PubMedCrossRefGoogle Scholar
  43. 43.
    Deng Y, Ren X, Yang L et al. A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 2003; 115(1):61–70.PubMedCrossRefGoogle Scholar
  44. 44.
    Wu H. Assembly of post-receptor signaling complexes for the tumor necrosis factor receptor superfamily. Adv Protein Chem 2004; 68:225–79.PubMedGoogle Scholar
  45. 45.
    Park YC, Burkitt V, Villa AR et al. Structural basis for self-association and receptor recognition of human TRAF2. Nature 1999; 398(6727):533–538.PubMedCrossRefGoogle Scholar
  46. 46.
    Murzin AG, Brenner SE, Hubbard T et al. SCOP: A structural classification of proteins database for the investigation of sequences and structures. J Mol Biol 1995; 247(4):536–540.PubMedCrossRefGoogle Scholar
  47. 47.
    Holm L, Sander C. Dali: A network tool for protein structure comparison. Trends Biochem Sci 1995; 20(11):478–480.PubMedCrossRefGoogle Scholar
  48. 48.
    Mcwhirter SM, Pullen SS, Holton JM et al. Crystallographic analysis of CD40 recognition and signaling by human TRAF2. Proc Natl Acad Sci USA 1999; 96(15):8408–8413.PubMedCrossRefGoogle Scholar
  49. 49.
    Ye H, Park YC, Kreishman M et al. The structural basis for the recognition of diverse receptor sequences by TRAF2. Mol Cell 1999; 4(3):321–330PubMedCrossRefGoogle Scholar
  50. 50.
    Uren AG, Vaux DL. Traf proteins and meprins share a conserved domain. Trends Biochem Sci 1996; 21(7):244–245.PubMedCrossRefGoogle Scholar
  51. 51.
    Zapata JM, Pawlowski K, Haas E et al. A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains. J Biol Chem 2001; 276(26):24242–24252.PubMedCrossRefGoogle Scholar
  52. 52.
    Polekhina G, House CM, Traficante N et al. Siah ubiquitin ligase is structurally related to TRAF and modulates TNF-alpha signaling. Nat Struct Biol 2002; 9(1):68–75.PubMedCrossRefGoogle Scholar
  53. 53.
    Gruber M, Lupas AN. Historical review: Another 50th anniversary—New periodicities in coiled coils. Trends Biochem Sci 2003; 28(12):679–685.PubMedCrossRefGoogle Scholar
  54. 54.
    Janin J, Miller S, Chothia C. Surface, subunit interfaces and interior of oligomeric proteins. J Mol Biol 1988; 204(1):155–164.PubMedCrossRefGoogle Scholar
  55. 55.
    Harbury PB, Zhang T, Kim PS et al. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 1993; 262(5138):1401–1407.PubMedCrossRefGoogle Scholar
  56. 56.
    Wolf E, Kim PS, Berger B. Multicoil: A program for predicting two-and three-stranded coiled coils. Protein Sci 1997; 6(6):1179–1189.PubMedCrossRefGoogle Scholar
  57. 57.
    Aizawa S, Nakano H, Ishida T et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem 1997; 272(4):2042–2045.PubMedCrossRefGoogle Scholar
  58. 58.
    Akiba H, Nakano H, Nishinaka S et al. CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-KappaB and stress-activated protein kinase/C-Jun N-terminal kinase via TRAF2, TRAF5, and NF-KappaB-inducing kinase. J Biol Chem 1998; 273(21):13353–13358.PubMedCrossRefGoogle Scholar
  59. 59.
    Boucher LM, Marengere LE, Lu Y et al. Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily. Biochem Biophys Res Commun 1997; 233(3):592–600.PubMedCrossRefGoogle Scholar
  60. 60.
    Brodeur SR, Cheng G, Baltimore D et al. Localization of the major NF-KappaB-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs. J Biol Chem 1997; 272(32):19777–19784.PubMedCrossRefGoogle Scholar
  61. 61.
    Devergne O, Hatzivassiliou E, Izumi KM et al. Association of TRAF1, TRAF2, and TRAF3 with an epstein-barr virus LMP1 domain important for B-lymphocyte transformation: Role in NF-KappaB activation. Mol Cell Biol 1996; 16(12):7098–7108.PubMedGoogle Scholar
  62. 62.
    Franken M, Devergne O, Rosenzweig M et al. Comparative analysis identifies conserved tumor necrosis factor receptor-associated factor 3 binding sites in the human and simian epstein-barr virus oncogene LMP1. J Virol 1996; 70(11):7819–7826.PubMedGoogle Scholar
  63. 63.
    Gedrich RW, Gilfillan MC, Duckett CS et al. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem 1996; 271(22):12852–12858.PubMedCrossRefGoogle Scholar
  64. 64.
    Sandberg M, Hammerschmidt W, Sugden B. Characterization of Lmp-1’s association with TRAF1, TRAF2, and TRAF3. J Virol 1997; 71(6):4649–4656.PubMedGoogle Scholar
  65. 65.
    Arch RH, Thompson CB. 4-1bb and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor KappaB. Mol Cell Biol 1998; 18(1):558–565.PubMedGoogle Scholar
  66. 66.
    Tong L, Qian C, Massariol MJ et al. Conserved mode of peptidomimetic inhibition and substrate recognition of human cytomegalovirus protease. Nat Struct Biol 1998; 5(9):819–826.PubMedCrossRefGoogle Scholar
  67. 67.
    Kuriyan J, Cowburn D. Modular peptide recognition domains in eukaryotic signaling. Annu Rev Biophys Biomol Struct 1997; 26:259–88, (259–288).PubMedCrossRefGoogle Scholar
  68. 68.
    Lim WA, Richards FM, Fox RO. Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains. Nature 1994; 372(6504):375–379.PubMedCrossRefGoogle Scholar
  69. 69.
    Stern LJ, Brown JH, Jardetzky TS et al. Crystal structure of the human class Ii MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994; 368(6468):215–221.PubMedCrossRefGoogle Scholar
  70. 70.
    Cheng G, Baltimore D. Tank, A coinducer with TRAF2 of TNF-and CD 40l-mediated NF-KappaB activation. Genes Dev 1996; 10(8):963–973.PubMedCrossRefGoogle Scholar
  71. 71.
    Rothe M, Xiong J, Shu HB et al. I-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction. Proc Natl Acad Sci USA 1996; 93(16):8241–8246.PubMedCrossRefGoogle Scholar
  72. 72.
    Pullen SS, Dang TT, Crute JJ et al. Cd40 signaling through tumor necrosis factor receptor-associated factors (TRAFs). Binding site specificity and activation of downstream athways by Distinct TRAFs. J Biol Chem 1999; 274(20):14246–14254.PubMedCrossRefGoogle Scholar
  73. 73.
    Ye H, Wu H. Thermodynamic characterization of the interaction between TRAF2 and tumor necrosis factor receptor peptides by isothermal titration calorimetry. Proc Natl Acad Sci USA 2000; 97(16):8961–8966.PubMedCrossRefGoogle Scholar
  74. 74.
    Ladbury JE. Counting the calories to stay in the groove. Structure 1995; 3(7):635–639.PubMedCrossRefGoogle Scholar
  75. 75.
    Park YC, Ye H, Hsia C et al. A novel mechanism of TRAF signaling revealed by structural and functional analyses of the TRADD-TRAF2 interaction. Cell 2000; 101(7):777–787.PubMedCrossRefGoogle Scholar
  76. 76.
    Tsao DH, Mcdonagh T, Telliez JB et al. Solution structure of N-TRADD and characterization of the interaction of N-TRADD and C-TRAF2, a key step in the TNFR1 signaling pathway. Mol Cell 2000; 5(6):1051–1057.PubMedCrossRefGoogle Scholar
  77. 77.
    Qrengo CA, Thornton JM. Alpha plus beta folds revisited: Some favoured motifs. Structure 1993; 1(2):105–120.CrossRefGoogle Scholar
  78. 78.
    Ni CZ, Welsh K, Leo E et al. Molecular basis for CD40 signaling mediated by TRAF3. Proc Natl Acad Sci USA 2000; 97(19):10395–10399.PubMedCrossRefGoogle Scholar
  79. 79.
    Rothe M, Pan MG, Henzel WJ et al. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995; 83(7):1243–1252.PubMedCrossRefGoogle Scholar
  80. 80.
    Pullen SS, Labadia ME, Ingraham RH et al. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry 1999; 38(31):10168–10177.PubMedCrossRefGoogle Scholar
  81. 81.
    Grell M, Douni E, Wajant H et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83(5):793–802.PubMedCrossRefGoogle Scholar
  82. 82.
    Hodgkin PD, Chin SH, Bartell G et al. The importance of efficacy and partial agonism in evaluating models of b lymphocyte activation. Int Rev Immunol 1997; 15(1–2):101–127.PubMedGoogle Scholar
  83. 83.
    Kehry MR, Castle BE. Regulation of CD40 ligand expression and use of recombinant CD40 ligand for studying b cell growth and differentiation. Semin Immunol 1994; 6(5):287–294.PubMedCrossRefGoogle Scholar
  84. 84.
    Heller RA, Song K, Fan N et al. The P70 tumor necrosis factor receptor mediates cytotoxicity. Cell 1992; 70(1):47–56.PubMedCrossRefGoogle Scholar
  85. 85.
    Vandenabeele P, Declercq W, Vanhaesebroeck B et al. Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells. J Immunol 1995; 154(6):2904–2913.PubMedGoogle Scholar
  86. 86.
    Weiss T, Grell M, Hessabi B et al. Enhancement of TNF receptor P60-mediated cytotoxicity by TNF receptor P80: Requirement of the TNF receptor-associated factor-2 binding site. J Immunol 1997; 158(5):2398–2404.PubMedGoogle Scholar
  87. 87.
    Haridas V, Darnay BG, Natarjan K et al. Overexpression of the P80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-Kappa B activation, and c-jun kinase activation. J Immunol 1998; 160(7):3152–3162.PubMedGoogle Scholar
  88. 88.
    Chan FK, Lenardo MJ. A crucial role for P80 TNF-R2 in amplifying P60 TNF-R1 apoptosis signals in T lymphocytes. Eur J Immunol 2000; 30(2):652–660.PubMedCrossRefGoogle Scholar
  89. 89.
    Grell M, Zimmermann G, Gottfried E et al. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: A role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J 1999; 18(11):3034–3043.PubMedCrossRefGoogle Scholar
  90. 90.
    Duckett CS, Thompson CB. CD30-dependent degradation of TRAF2: Implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev 1997; 11(21):2810–2821.PubMedGoogle Scholar
  91. 91.
    Li C, Ni CZ, Havert ML et al. Downstream regulator tank binds to the CD40 recognition site on TRAF3. Structure (Camb) 2002; 10(3):403–411.CrossRefGoogle Scholar
  92. 92.
    Li C, Norris PS, Ni CZ et al. Structurally distinct recognition motifs in lymphotoxin-beta receptor and CD40 for tumor necrosis factor receptor-associated factor (TRAF)-mediated signaling. J Biol Chem 2003; 278(50):50523–50529.PubMedCrossRefGoogle Scholar
  93. 93.
    Ye H, Arron JR, Lamothe B et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 2002; 418(6896):443–447.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2007

Authors and Affiliations

  • Jee Y. Chung
  • Miao Lu
  • Qian Yin
  • Hao Wu
    • 1
  1. 1.Department of BiochemistryWeill Medical College of Cornell UniversityNew YorkUSA

Personalised recommendations